Just before the 23andMe SPAC deal closed, the stock belonging to its merger partner ... giving investors the impression it is ...

Me collected information from survey questions about personal health and beyond, such as drinking habits and risk tolerance.

23andme says it owns the aggregated genetic data of its customers, meaning it can sell it to the highest bidder ...

Genetic testing company 23andMe (ME) has won court approval to sell its most valuable asset, customer DNA data, despite ...

The direct-to-consumer DNA testing service 23andMe filed for bankruptcy earlier this month, putting millions of customers' ...

Me promised to tell you where you came from. Now, it’s not clear where your genetic data is going. With a Chapter 11 filing, ...

But since 23andMe is not a medical provider it does not have to abide by standard privacy policies that must be followed at a doctor's office. Such services are "not regulated well," said Ayday.

Just before the 23andMe SPAC deal closed, the stock belonging to ... giving investors the impression it is a risk-free investment. Some companies do not find appropriate acquisition targets ...

23andMe bankruptcy underscores the risk of investing in most SPACs ... whose mission is to make acquisitions. Then the SPAC converts its ticker symbol and name over to one matching the name ...

23andMe is going bankrupt — underscoring the great risks of investing in many of the companies that have gone public via mergers with special-purpose acquisition corporations. When companies opt ...